HistoIndex pioneers stain-free, fully automated biophotonic SHG imaging combined with AI-based analysis to visualize and quantify fibrosis for clinical research and pharmaceutical drug development. The company’s core products support fibrosis assessment and precision medicine for metabolic dysfunction-associated steatohepatitis (MASH). HistoIndex recently launched its first Laboratory Developed Test (LDT), FibroSIGHT™, now available for order in the US. The firm intends to expand HistoIndex-partnered laboratories and operations within the US and to develop next-generation AI-powered SHG digital pathology tests for MASH patients. Founded in 2010 and based in Singapore, HistoIndex integrates research from pivotal clinical trials with clinical practice to accelerate drug development and improve patient outcomes. The company says its solutions are used to improve assessment of fibrosis changes and drug efficacy.

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

May 2025